Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 15210 | 18.36 |
09:34 ET | 4205 | 18.3811 |
09:36 ET | 4830 | 18.75 |
09:38 ET | 8562 | 18.8232 |
09:39 ET | 5296 | 18.8 |
09:41 ET | 8988 | 18.73 |
09:45 ET | 2715 | 18.79 |
09:48 ET | 4635 | 18.84 |
09:50 ET | 4223 | 18.85 |
09:52 ET | 2784 | 18.8 |
09:54 ET | 7272 | 18.74 |
09:56 ET | 504 | 18.635 |
09:57 ET | 3877 | 18.705 |
09:59 ET | 1044 | 18.615 |
10:01 ET | 200 | 18.525 |
10:03 ET | 650 | 18.4935 |
10:08 ET | 1050 | 18.276 |
10:10 ET | 512 | 18.18 |
10:12 ET | 704 | 18.24 |
10:14 ET | 792 | 18.27 |
10:17 ET | 200 | 18.29 |
10:19 ET | 100 | 18.28 |
10:21 ET | 561 | 18.29 |
10:24 ET | 100 | 18.31 |
10:26 ET | 200 | 18.235 |
10:32 ET | 484 | 18.22 |
10:35 ET | 151 | 18.2342 |
10:37 ET | 200 | 18.27 |
10:39 ET | 107 | 18.31 |
10:44 ET | 257 | 18.28 |
10:46 ET | 200 | 18.24 |
10:48 ET | 200 | 18.22 |
10:53 ET | 100 | 18.19 |
10:55 ET | 100 | 18.25 |
11:00 ET | 500 | 18.26 |
11:02 ET | 100 | 18.28 |
11:04 ET | 200 | 18.295 |
11:06 ET | 500 | 18.275 |
11:08 ET | 100 | 18.25 |
11:11 ET | 100 | 18.275 |
11:15 ET | 600 | 18.3475 |
11:20 ET | 250 | 18.363 |
11:22 ET | 100 | 18.32 |
11:26 ET | 100 | 18.37 |
11:29 ET | 100 | 18.35 |
11:31 ET | 622 | 18.37 |
11:33 ET | 1627 | 18.34 |
11:36 ET | 100 | 18.28 |
11:38 ET | 100 | 18.28 |
11:40 ET | 200 | 18.28 |
11:42 ET | 422 | 18.28 |
11:44 ET | 200 | 18.28 |
11:45 ET | 200 | 18.28 |
11:47 ET | 100 | 18.28 |
11:49 ET | 111 | 18.28 |
11:51 ET | 400 | 18.26 |
11:54 ET | 600 | 18.28 |
11:56 ET | 1300 | 18.325 |
11:58 ET | 100 | 18.31 |
12:00 ET | 897 | 18.37 |
12:02 ET | 1244 | 18.3 |
12:05 ET | 627 | 18.27 |
12:07 ET | 557 | 18.28 |
12:09 ET | 217 | 18.299 |
12:14 ET | 100 | 18.31 |
12:16 ET | 700 | 18.335 |
12:18 ET | 100 | 18.335 |
12:20 ET | 500 | 18.31 |
12:21 ET | 100 | 18.3 |
12:27 ET | 100 | 18.31 |
12:30 ET | 200 | 18.315 |
12:36 ET | 1200 | 18.27 |
12:38 ET | 100 | 18.27 |
12:45 ET | 1800 | 18.26 |
12:48 ET | 700 | 18.26 |
12:50 ET | 500 | 18.2 |
12:54 ET | 100 | 18.175 |
12:57 ET | 100 | 18.155 |
12:59 ET | 146 | 18.145 |
01:03 ET | 400 | 18.19 |
01:10 ET | 300 | 18.2 |
01:12 ET | 400 | 18.18 |
01:15 ET | 500 | 18.16 |
01:17 ET | 400 | 18.19 |
01:24 ET | 600 | 18.17 |
01:26 ET | 759 | 18.15 |
01:28 ET | 200 | 18.135 |
01:30 ET | 1000 | 18.11 |
01:32 ET | 1100 | 18.125 |
01:33 ET | 200 | 18.09 |
01:37 ET | 100 | 18.1 |
01:39 ET | 1100 | 18.17 |
01:42 ET | 1700 | 18.24 |
01:44 ET | 100 | 18.22 |
01:46 ET | 900 | 18.2 |
01:48 ET | 100 | 18.2 |
01:50 ET | 500 | 18.2 |
01:51 ET | 100 | 18.2 |
01:53 ET | 327 | 18.2 |
01:55 ET | 1100 | 18.23 |
01:57 ET | 1027 | 18.31 |
02:00 ET | 100 | 18.31 |
02:02 ET | 550 | 18.311 |
02:04 ET | 600 | 18.31 |
02:06 ET | 1300 | 18.27 |
02:08 ET | 1000 | 18.24 |
02:09 ET | 200 | 18.24 |
02:15 ET | 1806 | 18.27 |
02:18 ET | 100 | 18.265 |
02:26 ET | 100 | 18.25 |
02:27 ET | 699 | 18.27 |
02:29 ET | 100 | 18.27 |
02:31 ET | 100 | 18.3 |
02:36 ET | 400 | 18.31 |
02:40 ET | 508 | 18.4 |
02:42 ET | 1100 | 18.395 |
02:44 ET | 2300 | 18.36 |
02:47 ET | 760 | 18.335 |
02:49 ET | 100 | 18.335 |
02:51 ET | 2629 | 18.37 |
02:54 ET | 100 | 18.365 |
02:56 ET | 811 | 18.355 |
02:58 ET | 2138 | 18.35 |
03:00 ET | 700 | 18.36 |
03:02 ET | 700 | 18.34 |
03:07 ET | 443 | 18.4 |
03:09 ET | 300 | 18.41 |
03:12 ET | 600 | 18.4 |
03:14 ET | 1114 | 18.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 215.6x | --- |
Dynavax Technologies Corp | 1.5B | 222.7x | --- |
Zai Lab Ltd | 1.7B | -4.9x | --- |
BioCryst Pharmaceuticals Inc | 1.4B | -6.2x | --- |
CareDx Inc | 801.0M | -4.4x | --- |
MannKind Corp | 1.4B | 213.2x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 215.6x |
Price/Sales (TTM) | 4.2 |
Price/Cash Flow (TTM) | 117.6x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.